Key result
Hyperhomocysteinemia is linked to ~78% lower serum adropin levels in CAD patients.
Why the study?
The antagonistic effects of homocysteine and adropin on endothelial function and their association with CAD severity were not well characterized.
Is there an association between serum levels of adropin and homocysteine and the severity of coronary artery disease?
Cross-Sectional (n=86)
Is there an association between serum levels of adropin and homocysteine and the severity of coronary artery disease?
In patients with coronary artery disease, hyperhomocysteinemia is associated with significantly lower adropin levels and worse glycemic control.
Answers are grounded in this paper and cite their sources.
Hyperhomocysteinemia-associated adropin reduction in CAD is hypothesis-generating; prospective studies needed to clarify links with severity or glycemic control.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Hady et al. (2023) conducted a cross-sectional in Coronary Artery Disease (n=86). Hyperhomocysteinemia vs. Normal homocysteine levels was evaluated on Serum adropin levels. Hyperhomocysteinemia was associated with significantly lower serum adropin levels (1.6 vs 7.4) compared to normal homocysteine levels in patients with coronary artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: